Celastrol / STAT3 Cancer Research Results

Cela, Celastrol: Click to Expand ⟱
Features:

Celastrol — a quinone methide pentacyclic triterpenoid natural product isolated mainly from Tripterygium wilfordii and related Celastraceae plants. It is best classified as a pleiotropic redox-reactive small molecule with proteostasis-disrupting, anti-inflammatory, and anticancer activity. Standard abbreviations include Cel and CeT. In oncology, celastrol is best viewed as a preclinical multi-target stress inducer rather than a selective single-node inhibitor, with recurring emphasis on thiol-reactive proteostasis disruption, NF-κB suppression, ROS-linked mitochondrial injury, and context-dependent inhibition of STAT3 and PI3K/AKT signaling. Clinically important caveats are poor water solubility, poor oral bioavailability, rapid disposition, and a narrow therapeutic window that has driven strong interest in nanoformulations and conjugates.

Primary mechanisms (ranked):

  1. Proteostasis disruption with functional HSP90 inhibition and heat-shock response activation
  2. NF-κB pathway suppression through inhibition of pro-survival inflammatory signaling
  3. ROS elevation with mitochondrial dysfunction and intrinsic apoptosis
  4. JAK2/STAT3 axis inhibition in responsive tumor contexts
  5. Secondary down-modulation of PI3K/AKT/mTOR and related growth-survival signaling
  6. Context-dependent suppression of invasion, angiogenesis, and metastatic programs including CXCR4 and HIF-1-related outputs
  7. Chemosensitization and stress-vulnerability amplification in selected resistant tumor models

Bioavailability / PK relevance: Celastrol is practically insoluble or very poorly soluble in water, has poor oral bioavailability, and shows dose-limiting systemic toxicity; delivery systems are commonly used to improve exposure and reduce off-target injury.

In-vitro vs systemic exposure relevance: Many mechanistic and cytotoxicity studies use low-micromolar concentrations that are difficult to reproduce safely with conventional systemic dosing. Some pathway effects may still occur at lower exposures, but direct tumoricidal effects are often concentration-limited without advanced formulations.

Clinical evidence status: Strong preclinical oncology signal; early translational and formulation work; no approved cancer indication. Human clinical registration appears limited to non-oncology safety/other exploratory studies rather than established anticancer efficacy trials. *** Appears more useful used at lower doses in combined treatment approaches.

Celastrol—a bioactive compound extracted from traditional Chinese medicinal plants such as Tripterygium wilfordii (Thunder God Vine).

Pathways:
-inhibit NF-κB activation
-disrupt the function of chaperone proteins like HSP90 and HSP70, which are often overexpressed in cancer cells
-attenuate Akt phosphorylation and downstream mTOR signaling
-modulate components of the MAPK pathway, including ERK, JNK, and p38.
-increase intracellular ROS levels in cancer cells
-inhibiting STAT3

Celastrol mechanistic map in cancer

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 HSP90 proteostasis disruption ↓ client protein stability; ↑ heat-shock stress ↑ stress response (dose-dependent) P/R Destabilization of oncogenic signaling networks Mechanistically central and industry-relevant. Celastrol behaves as a thiol-reactive disruptor of chaperone-dependent proteostasis rather than a highly selective kinase inhibitor.
2 NF-κB inflammatory survival signaling ↓ ↓ inflammatory tone R/G Reduced survival, proliferation, cytokine signaling, and invasion One of the most reproducible anticancer themes; also helps explain anti-inflammatory overlap outside oncology.
3 Mitochondrial ROS increase ↑ (primary; dose-dependent) ↑ (high concentration only) P/R Oxidative stress overload and stress sensitization The quinone methide scaffold is redox-reactive. ROS often acts upstream of mitochondrial depolarization, apoptosis, and therapy sensitization.
4 Mitochondria and intrinsic apoptosis MMP ↓; Bax/Bcl-2 balance toward apoptosis; caspases ↑ ↑ injury at higher exposure R/G Apoptotic tumor cell death Usually linked to ROS and proteotoxic stress rather than an isolated primary target.
5 JAK2 STAT3 signaling ↓ (context-dependent) ↔ R/G Reduced proliferation, survival, and inflammatory transcription Supported in multiple tumor models, including myeloma and more recent metastatic-cancer work, but not necessarily dominant in every model.
6 PI3K AKT mTOR axis ↓ (secondary) ↔ / ↓ R/G Anabolic and survival suppression Often appears downstream of broader stress and chaperone disruption.
7 Invasion metastasis and angiogenesis programs CXCR4 ↓; motility ↓; VEGF signaling ↓; HIF-1α ↔ (context-dependent) ↔ G Reduced metastatic competence and tumor vascular support HIF-1-related effects are mixed across sources and models; anti-invasive and anti-angiogenic effects are better supported than a uniform HIF-1α direction.
8 NRF2 antioxidant response ↑ adaptive defense or overwhelm (context-dependent) ↑ cytoprotective stress response R/G Bidirectional redox adaptation Relevant, but not a clean core anticancer mechanism. NRF2 activation can be protective in normal tissue yet may also buffer tumor oxidative stress in some settings.
9 Chemosensitization ↑ therapy response ↔ / toxicity risk G Overcoming resistance in selected models Supported especially where NF-κB/STAT3-dependent resistance is prominent; still largely preclinical.
10 Clinical Translation Constraint Exposure limited Toxicity limited — Narrow therapeutic window Poor solubility, poor oral bioavailability, rapid metabolism/disposition, and organ-toxicity risk are major barriers to systemic oncology use.

TSF legend:
P: 0–30 min (direct redox/protein interactions)
R: 30 min–3 hr (acute stress and signaling shifts)
G: >3 hr (gene regulation and phenotype outcomes)
STAT3, Signal transducer and activator of transcription 3: Click to Expand ⟱
Source:
Type: Oncogene
Stat3 (Signal Transducer and Activator of Transcription 3) is a transcription factor that plays a crucial role in various cellular processes, including cell growth, survival, differentiation, and immune response.
Stat3 is frequently found to be constitutively activated in many types of cancers, including breast, prostate, lung, and head and neck cancers. (associated with poor prognosis and reduced survival.)

-STAT3 is typically activated by cytokines (such as IL-6) and growth factors binding to their respective receptors.
-Activated STAT3 upregulates the expression of genes that promote cell cycle progression (e.g., cyclin D1) and anti-apoptotic proteins (e.g., Bcl-2, Bcl-xL).
Scientific Papers found: Click to Expand⟱
5948- Cela,    Recent Trends in anti-tumor mechanisms and molecular targets of celastrol
TumCP↓, TumCCA↑, Apoptosis↑, TumAuto↑, TumCI↓, TumMeta↓, Imm↝, angioG↓, Cyt‑c↑, ROS↑, BAX↑, Casp3↑, Casp9↑, cl‑PARP↑, PrxII↓, ER Stress↑, mtDam↑, CHOP↑, Inflam↓, NF-kB↓, CXCR4↓, MMP9↓, IL6↓, TNF-α↓, HSP90↓, neuroP↑, STAT3↓, Prx↓, HO-1↑, eff↑, eff↑, BioAv↑, toxicity↑, CardioT↑, hepatoP↓,
5946- Cela,    The anti-cancer mechanism of Celastrol by targeting JAK2/STAT3 signaling pathway in gastric and ovarian cancer
- in-vitro, Var, NA
toxicity⇅, toxicity↓, TumCG↓, ROS↑, IL6↓, JAK2↓, STAT3↓,
5942- Cela,    Celastrol elicits antitumor effects by inhibiting the STAT3 pathway through ROS accumulation in non-small cell lung cancer
- vitro+vivo, NSCLC, H460 - in-vitro, NSCLC, PC9
TumCG↓, TumCP↓, TumMeta↓, ROS↑, ER Stress↑, p‑STAT3↓, Apoptosis↑, eff↓, TumCG↓, IL6↓, other↝,
5939- Cela,  Chemo,    Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells
- in-vitro, Melanoma, U266 - in-vitro, Melanoma, RPMI-8226
TumCP↓, ChemoSen↑, cycD1/CCND1↓, Bcl-2↓, survivin↓, XIAP↓, Mcl-1↓, NF-kB↓, IL6↓, STAT3↓, Apoptosis↑, TumCCA↑, Casp3↑, HSP90↓, HO-1↑, JAK2↓, Src↓, Akt↑,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

HO-1↑, 2,   Prx↓, 1,   PrxII↓, 1,   ROS↑, 3,  

Mitochondria & Bioenergetics ⓘ

mtDam↑, 1,   XIAP↓, 1,  

Cell Death ⓘ

Akt↑, 1,   Apoptosis↑, 3,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 2,   Casp9↑, 1,   Cyt‑c↑, 1,   Mcl-1↓, 1,   survivin↓, 1,  

Transcription & Epigenetics ⓘ

other↝, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   ER Stress↑, 2,   HSP90↓, 2,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 1,  

DNA Damage & Repair ⓘ

cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

Src↓, 1,   STAT3↓, 3,   p‑STAT3↓, 1,   TumCG↓, 3,  

Migration ⓘ

MMP9↓, 1,   TumCI↓, 1,   TumCP↓, 3,   TumMeta↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,  

Immune & Inflammatory Signaling ⓘ

CXCR4↓, 1,   IL6↓, 4,   Imm↝, 1,   Inflam↓, 1,   JAK2↓, 2,   NF-kB↓, 2,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   ChemoSen↑, 1,   eff↓, 1,   eff↑, 2,  

Clinical Biomarkers ⓘ

IL6↓, 4,  

Functional Outcomes ⓘ

CardioT↑, 1,   hepatoP↓, 1,   neuroP↑, 1,   toxicity↓, 1,   toxicity↑, 1,   toxicity⇅, 1,  
Total Targets: 50

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: STAT3, Signal transducer and activator of transcription 3
4 Celastrol
1 Chemotherapy
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:317  Target#:373  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page